No abstract

Objective To evaluate the efficacy and safety of transResults Symptom scores improved by 67% and residual volumes by 72%; the mean maximal flow rate urethral electrovaporization of the prostate (TUVP), using a grooved roller electrode, for the surgical increased from 8.5 mL/s (range 3.5-14) before treatment to 20.5 mL/s (range 4.5-39.0) at the same 4 treatment of symptomatic benign prostatic hypertrophy (BPH). month review. The procedure was simple and safe, with a mean operative duration of 35 min (range Patients and methods TUVP was carried out using a grooved roller electrode, pure-cutting diathermy and 20-65), and no patients required a blood transfusion. Most patients had their catheters removed within 24 h a standard irrigating resectoscope to rapidly heat prostatic tissue to >100°C, resulting in vaporization and were discharged on the second day after treatment. and cavitation of the prostatic adenoma. Over a 10 month period, 116 patients (mean age 69.8 years,Conclusion The effectiveness of TUVP in improving symptoms and flow rates in patients with BPH was range 51-93) with symptomatic BPH (confirmed by a symptom score, urinary flow rate and an ultrasonoestablished. With minimal capital expenditure and a reduced in-patient stay, TUVP appears to have several graphic estimate of residual volume) were treated by TUVP. Patients with carcinoma of the prostate, an advantages over other surgical treatments for BPH, although continued follow-up is needed to establish elevated level of prostate-specific antigen or those in chronic urinary retention were excluded from the the long-term results.

No abstract

No abstract

No abstract